Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-122 in Refractory Exudative AMD
NCT02555306Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2015
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in exudative age-related macular degeneration, sponsored by Santen Pharmaceutical. Started Sep 2015; status: completed.
02
Drugs
carotuximab
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT02555306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555306.